Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional)
ID: 357202Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/357202

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-25-069.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity titled "Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional)" aimed at promoting research into the effects of incretin mimetics on cancer risk. This initiative seeks to support preclinical and patient-based studies that explore the mechanisms by which these agents, including GLP-1 and dual GLP-1/GIP-1 receptor agonists, may influence cancer risk, particularly in relation to obesity-related cancers. The funding is available to a wide range of eligible applicants, including various educational institutions and organizations, with no cost-sharing requirement, and projects can span up to five years. Interested applicants should note that the application deadline is January 7, 2027, and can find more information by contacting NIH Grants Information at grantsinfo@nih.gov or visiting the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-25-069.html.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-25-069-Full-Announcement.html
    PAR-25-069.html
    The Department of Health and Human Services, through the National Cancer Institute (NCI), announces the funding opportunity for investigator-initiated studies exploring the impact of incretin mimetics, specifically GLP-1 and dual GLP-1/GIP-1 receptor agonists, on cancer risk. The initiative targets the reported associations between these drugs and cancer risks related to thyroid and prostate cancers, as well as potential beneficial effects in addressing obesity-related risk factors. Applicants are invited to submit proposals focusing on mechanisms underlying these associations while justifying choices of non-GLP-1 agents if proposed. The funding opportunity opens on January 5, 2025, with application deadlines set throughout the year. Eligible institutions include various higher education and governmental bodies, and no cost-sharing is required. The grants are not limited in budget but must reflect the project's needs, with a maximum project period of five years. Emphasis is placed on rigorous scientific design, potential for impactful results, and recruitment diversity in clinical trials, along with NIH policy compliance regarding data management and sharing. This opportunity aims to broaden research in cancer biology, encouraging innovative approaches to studying the off-target effects of incretin mimetics.
    Similar Opportunities
    Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a federal grant opportunity titled "Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional)" aimed at investigating how incretin mimetics, particularly GLP-1 and dual GLP-1/GIP-1 receptor agonists, influence cancer risk. The program seeks to promote preclinical and patient-based studies that explore the mechanisms by which these agents affect cancer, especially in relation to obesity-related cancers, while attracting talented scientists to focus on long-term outcomes rather than short-term effects like weight loss and diabetes. Eligible applicants include a wide range of organizations, such as higher education institutions, nonprofits, and foreign entities, with applications encouraged to begin submission starting January 5, 2024, for projects with a funding period of up to five years. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov, and the opportunity is set to close on January 7, 2027.
    Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a federal grant opportunity titled "Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)." This initiative aims to promote exploratory research into the biological mechanisms by which incretin mimetics, particularly GLP-1 and dual GLP-1/GIP-1 receptor agonists, influence cancer risk, with a focus on understanding their effects beyond diabetes treatment. The funding, which amounts to a maximum of $275,000 over two years, is intended to attract diverse researchers and institutions to fill significant gaps in current cancer biology research. Interested applicants should note that the application submission period begins on January 16, 2025, and can find further details and guidelines at the NIH grants website or by contacting NIH Grants Information at grantsinfo@nih.gov.
    Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the R21 exploratory research grant titled "Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics." This grant aims to support preclinical and patient-based studies that investigate how incretin mimetics, specifically GLP-1 and GIP-1 receptor agonists, influence cancer risk, particularly in relation to obesity-related cancers such as thyroid and prostate cancers. The funding, which amounts to a maximum of $275,000 over two years, is intended for projects that do not involve clinical trials, with applications opening in January 2024 and a submission deadline of January 7, 2027. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Mechanisms that Impact Cancer Risk after Bariatric Surgery (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for research investigating the mechanisms by which bariatric surgery impacts cancer risk, under the title "Mechanisms that Impact Cancer Risk after Bariatric Surgery (R01 Clinical Trial Optional)." This initiative aims to support studies that explore the long-term effects of bariatric surgery on cancer risk, moving beyond immediate outcomes such as weight loss and diabetes, and considering factors like sex, racial background, and procedure type. With a funding ceiling of $500,000 per year for up to five years, the program encourages innovative research proposals from a diverse range of eligible applicants, including educational institutions and community organizations. Applications are due by January 7, 2028, and interested parties can find more information by contacting NIH Grants Information at grantsinfo@nih.gov or visiting the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-25-043.html.
    Mechanisms that Impact Cancer Risk after Bariatric Surgery (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), is offering a funding opportunity titled "Mechanisms that Impact Cancer Risk after Bariatric Surgery (R21 Clinical Trial Not Allowed)." This grant aims to support innovative, investigator-initiated studies that explore how bariatric surgery influences cancer risk, moving beyond traditional short-term outcomes such as weight loss and diabetes management. Given the rising prevalence of obesity and the increasing number of bariatric surgeries performed in the U.S., this research is crucial for identifying new pathways for cancer prevention. The grant provides funding of up to $275,000 over two years, with applications due by January 16, 2025, and additional cycles available through 2026. For further inquiries, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-25-044.html.
    Mechanistic links between diet, lipid metabolism, and tumor growth and progression (U01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced a funding opportunity (PAR-23-051) aimed at investigating the mechanistic links between diet, lipid metabolism, and tumor growth and progression. This initiative seeks applications that explore how dietary patterns, particularly high-fat or ketogenic diets, influence cancer cell metabolism and tumor behavior, with a focus on the role of lipids in these processes. The program is designed to bridge the fields of nutrition and molecular metabolism, stimulate research, and develop tools to enhance understanding in this area, while emphasizing collaboration among investigators with expertise in nutrition. Applicants may request up to $500,000 annually for a maximum of five years, with the application deadline set for October 23, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Mechanistic links between diet, lipid metabolism, and tumor growth and progression (UH2 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Mechanistic links between diet, lipid metabolism, and tumor growth and progression (UH2 Clinical Trial Not Allowed)" aimed at exploring the connections between dietary factors and cancer biology. This initiative seeks applications that investigate the molecular mechanisms linking lipid metabolism to tumor growth and progression, with a particular focus on how dietary lipids influence the tumor microenvironment and associated health disparities. The program supports exploratory research with a maximum funding request of $275,000 in direct costs over two years, and applications are due by October 23, 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-25-118.html.
    Mechanistic links between diet, lipid metabolism, and tumor growth and progression (U01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Mechanistic links between diet, lipid metabolism, and tumor growth and progression (U01 Clinical Trial Not Allowed)" aimed at advancing research in the intersection of nutrition and cancer biology. This initiative seeks applications that investigate the molecular mechanisms by which lipid metabolism influences tumor dynamics, particularly focusing on the effects of dietary lipids and their interactions with the tumor microenvironment. The program is designed to bridge the fields of nutrition and cancer research, with a budget cap of $500,000 per year for up to five years, encouraging innovative studies, especially those involving high-fat or ketogenic diets. Interested applicants can find more information and application guidelines at the provided NIH link, with a submission deadline of October 23, 2025, and inquiries directed to grantsinfo@nih.gov.
    Mechanistic links between diet, lipid metabolism, and tumor growth and progression (UH2 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for a funding opportunity titled "Mechanistic links between diet, lipid metabolism, and tumor growth and progression," under the UH2 Clinical Trial Not Allowed activity code. This initiative aims to support fundamental studies that investigate the molecular mechanisms linking lipid metabolism to tumor growth, with a focus on bridging the fields of nutrition and molecular metabolism. The program is particularly significant as it addresses critical gaps in understanding the relationship between diet and cancer biology. The funding amount is capped at $275,000 over a two-year period, with applications due by October 23, 2025. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Early-Stage Preclinical Validation of Therapeutic Leads for Diseases of Interest to the NIDDK (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Early-Stage Preclinical Validation of Therapeutic Leads for Diseases of Interest to the NIDDK (R01 Clinical Trial Not Allowed)." This grant aims to support translational research that justifies later-phase therapeutic discovery and development efforts related to diseases such as obesity, diabetes, digestive disorders, and kidney diseases. The initiative encourages innovative research on novel small molecules and biologics, with a focus on therapeutics that significantly improve or differentiate from existing treatments. NIH anticipates awarding 3-4 grants annually, with budgets ranging from $250,000 to $300,000 per project for up to five years. Interested applicants must submit their proposals by January 7, 2025, and can reach out to the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries. Additional details can be found at http://grants.nih.gov/grants/guide/pa-files/PAR-22-111.html.